Related Experiment Video
Updated: Mar 21, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Targeting heart failure with preserved ejection fraction: current status and future prospects
Manreet Kanwar1, Claire Walter1, Megan Clarke1
1Department of Cardiology, Allegheny General Hospital, Pittsburgh, PA, USA.
Heart failure with preserved ejection fraction (HFpEF) is a major health issue with no approved treatments. Research is urgently needed to understand HFpEF causes and develop new therapies to improve patient outcomes.
Area of Science:
- Cardiology
- Clinical Medicine
- Translational Research
Background:
- Heart failure with preserved ejection fraction (HFpEF) presents a substantial challenge due to high prevalence, morbidity, mortality, and healthcare expenses.
- Significant gaps exist in understanding HFpEF pathophysiology, definition, and effective therapeutic targets.
Purpose of the Study:
- To highlight the urgent need for focused drug and device development for HFpEF.
- To emphasize the necessity of advancing the understanding of HFpEF pathophysiology.
Main Methods:
- Review of current literature and clinical trial landscape for HFpEF.
- Analysis of the unmet needs in HFpEF management.
Main Results:
- Currently, no therapies are approved to reduce mortality or hospitalizations in HFpEF patients.
- Several clinical trials are underway to address this therapeutic gap.
Conclusions:
- There is a critical need for accelerated drug and device development for HFpEF.
- Further research into HFpEF pathophysiology is essential for therapeutic advancements.
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management
Heart Failure II: Pathophysiology
Heart Failure I: Introduction
Cardiomyopathy V: Interprofessional Care

